Biogaia

Biogaia R&D per Employee

The R&D Spending per Employee of Biogaia (BIOG B.ST) as of Oct 30, 2026 is 732,417.72 SEK. In the previous year, R&D Spending per Employee was 994,329.11 SEK — a change of -26.34% (lower).

R&D per Employee

732,417.72SEK

YoY

-26.34%

Last updated:

R&D Spending per Employee of Biogaia is 2025 732,417.72 SEK. R&D Spending per Employee of Biogaia was 2024 994,329.11 SEK. It decreases by -26.34% lower compared to the previous year.

The Biogaia R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
631,278.48 SEK
Jan 1, 2019
664,879.75 SEK
Jan 1, 2020
662,424.05 SEK
Jan 1, 2021
667,512.66 SEK
Jan 1, 2022
675,981.01 SEK
Jan 1, 2023
675,797.47 SEK
Jan 1, 2024
994,329.11 SEK
Jan 1, 2025
732,417.72 SEK
The Biogaia R&D per Employee history
YEARR&D per EmployeeYoY
732,417.72SEK-26.34%
994,329.11SEK+47.13%
675,797.47SEK-0.03%
675,981.01SEK+1.27%
667,512.66SEK+0.77%
662,424.05SEK-0.37%
664,879.75SEK+5.32%
631,278.48SEK+31.76%
479,113.92SEK+18.66%
403,765.82SEK-10.47%
450,993.67SEK+32.28%
340,930.38SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biogaia Stock analysis

What does Biogaia do? BioGaia AB generates revenue through its probiotic product segments, primarily featuring Limosilactobacillus reuteri strains. The Paediatrics segment sells drops, gut health tablets, oral rehydration solutions, and cultures for licensee products. The Adult Health segment offers gut health tablets, oral health lozenges, and cultures integrated into dairy products by licensees. The Other segment includes royalties from development projects and revenue from CapAble's packaging solutions. Products are marketed globally to consumers seeking health benefits from probiotics, with licensees distributing branded items under agreements. The company targets health-conscious consumers through direct sales and licensed partnerships. Paediatrics products focus on infant and child health, while Adult Health products address digestive and oral wellness. CapAble, a subsidiary, contributes through packaging solutions, and royalties from development projects provide additional income streams. All segments operate under BioGaia's brand, leveraging documented health benefits of their probiotic strains. Biogaia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biogaia stock

R&D Spending per Employee of Biogaia is 732,417.72 SEK in 2025.

R&D Spending per Employee of Biogaia changed from 994,329.11 SEK to 732,417.72 SEK, representing a -26.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Biogaia since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Biogaia historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Biogaia

All Key Metrics — Biogaia